This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Relative Bioavailability of a Fentanyl Patch

This study has been completed.
Sponsor:
Information provided by:
Sandoz
ClinicalTrials.gov Identifier:
NCT00857753
First received: March 5, 2009
Last updated: March 27, 2017
Last verified: March 2009
  Purpose
Tohe purpose of this study is to demonstrate the bioequivalence of a fentanyl patch transdermal delivery system.

Condition Intervention Phase
Pain Drug: Fentanyl patch 25 ug/nr Sandoz Drug: Duragesic Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Relative Bioavailability of a Fentanyl PAtch Transdermal Delivery System (25 ug/hr) (Sandoz) Compared to Duragesic (Fentanyl Transdermal SYstem 25 ug/hr Patches (Alza)

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence according to US FDA guidelines [ Time Frame: 3 weeks ]

Enrollment: 40
Study Start Date: September 2006
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Fentanyl patch 25 ug/hr Sandoz
Drug: Fentanyl patch 25 ug/nr Sandoz
Active Comparator: 2
Duragesic Patch 25 ug/hr
Drug: Duragesic

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant abnormal findings on physical exam, medical history or clinical laboratory tests on screening.

Exclusion Criteria:

  • Negative test for HIV and hepatitis B and C
  • No history of drug or alcohol treatment
  • No allergies to opiates
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00857753

Sponsors and Collaborators
Sandoz
Investigators
Principal Investigator: Darin B. Brimhall, D.O. Novum Pharmaceutical Research Services
  More Information

Responsible Party: Eric Mittleberg, Ph.D., VP Product Development, Sandoz, Inc.
ClinicalTrials.gov Identifier: NCT00857753     History of Changes
Other Study ID Numbers: 10613401
Study First Received: March 5, 2009
Last Updated: March 27, 2017

Additional relevant MeSH terms:
Fentanyl
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics

ClinicalTrials.gov processed this record on August 22, 2017